These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20073471)

  • 1. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
    Mizuno CS; Chittiboyina AG; Shah FH; Patny A; Kurtz TW; Pershadsingh HA; Speth RC; Karamyan VT; Carvalho PB; Avery MA
    J Med Chem; 2010 Feb; 53(3):1076-85. PubMed ID: 20073471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
    Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
    J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
    Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
    Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
    Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
    Zhang J; Wang JL; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Bioorg Med Chem; 2012 Jul; 20(14):4208-16. PubMed ID: 22727371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
    Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
    Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
    Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
    J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
    Zhang J; Wang JL; Yu WF; Zhou ZM; Tao WC; Wang YC; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
    Eur J Med Chem; 2013 Nov; 69():44-54. PubMed ID: 24007859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
    Xiao J; Leung JC; Chan LY; Tang SC; Lai KN
    Clin Immunol; 2009 Aug; 132(2):266-76. PubMed ID: 19443277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High glucose enhances angiotensin-II-mediated peroxisome proliferation-activated receptor-gamma inactivation in human coronary artery endothelial cells.
    Min Q; Bai YT; Jia G; Wu J; Xiang JZ
    Exp Mol Pathol; 2010 Feb; 88(1):133-7. PubMed ID: 19796634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
    Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
    Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
    Towfighi A; Ovbiagele B
    Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
    Meyer M; Foulquier S; Dupuis F; Flament S; Grimaud L; Henrion D; Lartaud I; Monard G; Grillier-Vuissoz I; Boisbrun M
    Eur J Med Chem; 2018 Oct; 158():334-352. PubMed ID: 30223121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells.
    Kociecka B; Surazynski A; Miltyk W; Palka J
    Eur J Pharmacol; 2010 Feb; 628(1-3):51-6. PubMed ID: 19945454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
    Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.